Please login to the form below

Not currently logged in
Email:
Password:

Sativex

This page shows the latest Sativex news and features for those working in and with pharma, biotech and healthcare.

GW ascendant as epilepsy drug clears phase III trial

GW ascendant as epilepsy drug clears phase III trial

GW already makes fees and royalty revenues from cannabinoid-based drug called Sativex for moderate to severe spasticity in multiple sclerosis patients who have not responded adequately to other anti-spasticity

Latest news

  • NICE denies two drugs in new MS guidance NICE denies two drugs in new MS guidance

    NICE denies two drugs in new MS guidance. Sativex and Fampyra too costly for NHS in England. ... process”. Sativex. Sativex is licensed to treat moderate to severe spasticity in MS patients who have not responded adequately to other anti-spasticity

  • Cancer pain: opioids set to dominate Cancer pain: opioids set to dominate

    Phase III: opioid agonists. GW Pharmaceuticals has developed a buccal spray known as nabiximols or Sativex, which comprises delta-9-tetrahydrocannabinol (27mg/mL) and cannabidiol (25mg/mL), as an analgesic agent

  • Langland steals the pharma show at first Lions Health Langland steals the pharma show at first Lions Health

    Langland's advertisement for Bayer's Sativex - a winner at the Lions Health awards. ... Stealing the show in this year's pharma category was Langland, which picked up a trio of gold awards for its work on Bayer's multiple sclerosis spasticity brand

  • Almirall expands in US via $400m deal to buy Aqua Almirall expands in US via $400m deal to buy Aqua

    under 22m on the back of high roll-out costs for new products such as Sativex (nabiximols) for spasticity in multiple sclerosis (MS) and chronic obstructive pulmonary disorder (COPD) treatment Eklira

  • Almirall launches Sativex in Italy Almirall launches Sativex in Italy

    Almirall launches Sativex in Italy. Brings cannabis-based drug for multiple sclerosis spasticity to market. ... Almirall has launched its cannabinoid treatment Sativex for moderate to severe spasticity in multiple sclerosis (MS) patients in Italy.

More from news
Approximately 3 fully matching, plus 57 partially matching documents found.

Latest Intelligence

  • Death by Numbers Death by Numbers

    Not so. Take the example of this campaign for Sativex, a drug used in the treatment of Multiple Sclerosis. ... The obvious solution to the brief was an ingredient story - Sativex is derived from cannabis.

  • Interview: Jorge Gallardo, Almirall Interview: Jorge Gallardo, Almirall

    Also in 2011, we have launched Sativex, an oral spray for spasticity in multiple sclerosis, which will be deployed in Europe soon.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • GW hires Pfizer’s Kenneth Sommerville GW hires Pfizer’s Kenneth Sommerville

    GW's research is focused on the development of cannabinoids. This includes Sativex, which became the world's first plant-derived cannabinoid prescription drug when it was approved for multiple sclerosis ... This is an exciting time to be joining GW, with

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics